Moreover, given the fact that stroke represents a rather heterogenous syndrome, a combined panel incorporating BNP, GFAP, RDW, NLR, MMP-9, and AQP4 might represent a promising approach, both in research and in clinical practice, minimizing the effect of any individual biomarker. This evidence concerns the gene GFAP and Stroke.